Imperva Announces Preliminary Second Quarter 2016 Financial Results

Go back to Imperva Announces Preliminary Second Quarter 2016 Financial Results

Imperial Capital Reiterates Outperform on Imperva (IMPV) Following 2Q Preliminary Results

July 13, 2016 7:10 AM EDT

Imperial Capital reiterated an Outperform rating and $55.00 price target on Imperva (NYSE: IMPV) following the company's 2Q preliminary results. IMPV reported preliminary revenue of $57.5-58.0mn and adjusted net loss per share of ($0.20)-
($0.22). Results came in below Street revenue estimates of... More

Nomura Securities Cuts Price Target on Imperva (IMPV) Following Preliminary 2Q Results

July 12, 2016 7:42 AM EDT

Nomura Securities maintained a Buy rating on Imperva (NYSE: IMPV), and cut the price target to $55.00 (from $60.00), following the company's preliminary 2Q financial results. IMPV is expecting revenue to be in the range of $57.5-58.0mn, an 8% growth yoy. This is down from the previous revenue... More

Oppenheimer Remains Bullish on Imperva (IMPV) Following a Disappointing 2Q Pre-Announcement

July 12, 2016 7:33 AM EDT

Oppenheimer reiterated an Outperform rating and $60.00 price target on Imperva (NYSE: IMPV) following the company's 2Q pre-announcement. Revenue was guided in the range of $57.5-58M from previous guidance of $65.5-66.5M. LPS was guided $(0.20)-(0.22) from $(0.02)-(0.04). IMPV's weak performance was primarily driven by customers'... More

Deutsche Bank Downgrades Imperva (IMPV) to Hold

July 12, 2016 6:39 AM EDT

Deutsche Bank downgraded Imperva (NYSE: IMPV) from Buy to Hold with a price target of $43.00 (from $45.00). The change follow disappointing preliminary Q2 results.

"IMPV negatively pre-announced its Q216 numbers, and blamed longer sales cycles and smaller deals sizes for the weakness in... More